Amgen price target lowered to $315 from $319 at UBS

UBS analyst Trung Huynh lowered the firm’s price target on Amgen (AMGN) to $315 from $319 and keeps a Neutral rating on the shares. The firm notes a “strong” operational start to the year, but believes the investment in the pipeline growth tempers margin expansion, the analyst tells investors in a research note.